WallStreetZenWallStreetZen

NASDAQ: BCAB
Bioatla Inc Stock

$4.27+0.03 (+0.71%)
Updated Feb 3, 2023
BCAB Price
$4.27
Fair Value Price
$9.02
Market Cap
$160.58M
52 Week Low
$2.01
52 Week High
$12.15
P/E
-1.56x
P/B
1.13x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$102.33M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.33
Operating Cash Flow
-$87M
Beta
1.69
Next Earnings
Feb 27, 2023
Ex-Dividend
N/A
Next Dividend
N/A

BCAB Overview

BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.

Zen Score

Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how BCAB scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

BCAB ($4.27) is undervalued by 52.65% relative to our estimate of its Fair Value price of $9.02 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
BCAB ($4.27) is significantly undervalued by 52.65% relative to our estimate of its Fair Value price of $9.02 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
BCAB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more BCAB due diligence checks available for Premium users.

Be the first to know about important BCAB news, forecast changes, insider trades & much more!

BCAB News

Valuation

BCAB fair value

Fair Value of BCAB stock based on Discounted Cash Flow (DCF)
Price
$4.27
Fair Value
$9.02
Undervalued by
52.65%
BCAB ($4.27) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
BCAB ($4.27) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
BCAB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

BCAB price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-1.56x
Industry
10.7x
Market
15.09x

BCAB price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
1.13x
Industry
5.11x
BCAB is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

BCAB's financial health

Profit margin

Revenue
$0.0
Net Income
-$25.8M
Profit Margin
0%
BCAB's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$189.1M
Liabilities
$46.5M
Debt to equity
0.33
BCAB's short-term assets ($183.31M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BCAB's short-term assets ($183.31M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BCAB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$24.0M
Investing
-$58.0k
Financing
-$96.0k
BCAB's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

BCAB vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
BCAB$160.58M+0.71%-1.56x1.13x
XERS$160.46M-6.35%-1.13x2.92x
MACK$160.39M+0.25%-108.73x12.16x
CMRX$160.24M-1.09%1.04x0.58x
GLYC$161.99M+1.98%-3.03x3.37x

Bioatla Stock FAQ

What is Bioatla's quote symbol?

NASDAQ: BCAB) Bioatla trades on the NASDAQ under the ticker symbol BCAB. Bioatla stock quotes can also be displayed as NASDAQ: BCAB.

If you're new to stock investing, here's how to buy Bioatla stock.

What is the 52 week high and low for Bioatla (NASDAQ: BCAB)?

(NASDAQ: BCAB) Bioatla's 52-week high was $12.15, and its 52-week low was $2.01. It is currently -64.86% from its 52-week high and 112.44% from its 52-week low.

How much is Bioatla stock worth today?

(NASDAQ: BCAB) Bioatla currently has 37,607,297 outstanding shares. With Bioatla stock trading at $4.27 per share, the total value of Bioatla stock (market capitalization) is $160.58M.

Bioatla stock was originally listed at a price of $31.02 in Dec 16, 2020. If you had invested in Bioatla stock at $31.02, your return over the last 2 years would have been -86.23%, for an annualized return of -62.9% (not including any dividends or dividend reinvestments).

How much is Bioatla's stock price per share?

(NASDAQ: BCAB) Bioatla stock price per share is $4.27 today (as of Feb 3, 2023).

What is Bioatla's Market Cap?

(NASDAQ: BCAB) Bioatla's market cap is $160.58M, as of Feb 6, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Bioatla's market cap is calculated by multiplying BCAB's current stock price of $4.27 by BCAB's total outstanding shares of 37,607,297.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.